Nurix Therapeutics Inc (NASDAQ: NRIX) kicked off on Monday, up 7.77% from the previous trading day, before settling in for the closing price of $9.14. Over the past 52 weeks, NRIX has traded in a range of $8.18-$29.56.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 24.84% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -5.57%. With a float of $74.72 million, this company’s outstanding shares have now reached $76.23 million.
In an organization with 286 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 85.4%, operating margin of -408.87%, and the pretax margin is -369.08%.
Nurix Therapeutics Inc (NRIX) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Nurix Therapeutics Inc is 1.99%, while institutional ownership is 107.70%. The most recent insider transaction that took place on Mar 03 ’25, was worth 84,388. In this transaction Chief Financial Officer of this company sold 5,825 shares at a rate of $14.49, taking the stock ownership to the 33,724 shares. Before that another transaction happened on Mar 03 ’25, when Company’s Officer proposed sale 5,825 for $15.45, making the entire transaction worth $89,996.
Nurix Therapeutics Inc (NRIX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -5.57% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -2.57% during the next five years compared to -38.86% drop over the previous five years of trading.
Nurix Therapeutics Inc (NASDAQ: NRIX) Trading Performance Indicators
Take a look at Nurix Therapeutics Inc’s (NRIX) current performance indicators. Last quarter, stock had a quick ratio of 6.26. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 13.31.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.81, a number that is poised to hit -0.73 in the next quarter and is forecasted to reach -3.27 in one year’s time.
Technical Analysis of Nurix Therapeutics Inc (NRIX)
Let’s dig in a bit further. During the last 5-days, its volume was 1.34 million. That was better than the volume of 0.88 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 31.16%. Additionally, its Average True Range was 1.04.
During the past 100 days, Nurix Therapeutics Inc’s (NRIX) raw stochastic average was set at 11.20%, which indicates a significant decrease from 33.98% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 95.58% in the past 14 days, which was higher than the 63.38% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.25, while its 200-day Moving Average is $20.30. However, in the short run, Nurix Therapeutics Inc’s stock first resistance to watch stands at $10.16. Second resistance stands at $10.46. The third major resistance level sits at $10.96. If the price goes on to break the first support level at $9.36, it is likely to go to the next support level at $8.86. The third support level lies at $8.56 if the price breaches the second support level.
Nurix Therapeutics Inc (NASDAQ: NRIX) Key Stats
The company with the Market Capitalisation of 750.96 million has total of 76,236K Shares Outstanding. Its annual sales at the moment are 54,550 K in contrast with the sum of -193,570 K annual income. Company’s last quarter sales were recorded 13,280 K and last quarter income was -58,550 K.
